Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient

We present a case of a 15-year-old male diagnosed with multiple autoimmune conditions, including atopic dermatitis (AD), Crohn's disease (CD), alopecia areata (AA), and eosinophilic gastroenteropathy. After failure of previous therapies, the patient was successfully treated with upadacitinib, a Janus Kinase 1 (JAK-1) inhibitor. Significant improvement in skin and gastrointestinal symptoms, as well as hair regrowth, was observed following 16 weeks of treatment. This case highlights the therapeutic potential of JAK inhibitors like upadacitinib in managing complex autoimmune disorders that share common pathogenic pathways.

Authors

Institutions

Publication Details

Journal
Dermatology Reports
Published
2026-01-09
DOI
https://doi.org/10.4081/dr.2026.10165
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient

Sara Lambiase, Arnaldo Cioni, Edoardo Mortato, Marina Aloi et al.
Dermatology Reports
Dermatology and Skin Diseases
article

Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient

Sara Lambiase, Arnaldo Cioni, Edoardo Mortato, Marina Aloi, Ruslana Gaeta Shumak, Angela Fico, Enrico Matteini, Luca Bianchi, Ludovico Maria Rao, Elena Campione
article en

Abstract

We present a case of a 15-year-old male diagnosed with multiple autoimmune conditions, including atopic dermatitis (AD), Crohn's disease (CD), alopecia areata (AA), and eosinophilic gastroenteropathy. After failure of previous therapies, the patient was successfully treated with upadacitinib, a Janus Kinase 1 (JAK-1) inhibitor. Significant improvement in skin and gastrointestinal symptoms, as well as hair regrowth, was observed following 16 weeks of treatment. This case highlights the therapeutic potential of JAK inhibitors like upadacitinib in managing complex autoimmune disorders that share common pathogenic pathways.

Dermatology Reports
University of Rome Tor Vergata (IT), Policlinico Umberto I (IT), University of Bari Aldo Moro (IT)
Good health and well-being
Openalex Percentile: Top 93%
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.